ADVB — FY2026 Annual Financial Report Analysis

A paper profit from giving away the old business

Advanced Biomed Inc. is a Nasdaq-listed holding company that until this year developed blood tests for cancer through subsidiaries in Taiwan, Hong Kong and mainland China. This report covers its fiscal year 2026, the twelve months to June 30, 2026, from the annual report (10-K) filed on October 13, 2026 after a 15-day extension. During that year the company sold every one of its biotech subsidiaries and bought a small Hong Kong AI company, Acellent Technologies. That makes this the first annual report of what is effectively a different business.

The headline says ADVB earned $6.68M of net income ($5.33 per share), against a $3.26M loss a year earlier. That figure is an accounting effect. It includes a $14.02M "gain on disposal of subsidiaries" that brought in almost no cash. Without that gain the company lost $7.34M, more than twice the prior year's loss. The new AI business earned its first revenue: $127,637, all from a one-off agency fee.

At a glance

• $14.02M gain vs $0.51M of sale prices. The subsidiaries were sold for $23,000 (Hong Kong/China) and $490,000 (Taiwan). The gain comes from removing their debts from the books, not from cash coming in. Of the $513,000, only $23,000 had been received by year-end.
• $12.96M owed by the companies it sold, or 94% of total assets. ADVB's balance sheet now rests almost entirely on money owed by its former subsidiaries, which now belong to two individual buyers.
• $385,535 of cash at year-end vs $607,014 owed on a 10% shareholder loan that matures around mid-October 2026. The filing reports no repayment or extension.

The numbers

All figures in US dollars, in millions unless stated. "Continuing operations" means what ADVB still owns: the US parent and, from April 2026, Acellent. The sold biotech subsidiaries are reported separately as "discontinued operations" for both years. Per-share figures reflect a 1-for-20 reverse stock split on February 20, 2026.

Revenue was zero a year earlier, so a percentage growth rate isn't meaningful. The same applies to net income and EPS, which swung from a loss to a profit.

Why the continuing loss jumped

The continuing loss grew by $5.17M. Most of that is non-cash charges, which reduce profit on paper but don't use up cash:

• $2.92M "provision for expected credit losses": an estimate of money owed to ADVB that it now doesn't expect to collect, mostly from the former subsidiaries (see below).
• $1.73M of stock-based compensation. When ADVB bought Acellent with 270,000 new shares worth $1.75M (about $6.47 each), it treated only $12,891 as the purchase price. That was Acellent's entire asset, its cash. The other $1.73M was booked as pay to Acellent's seller for becoming ADVB's CEO and chairman, with no vesting conditions.
• $0.50M commitment fee, paid in shares to an investor for an equity-line financing facility. ADVB terminated that facility in July 2026 without ever drawing on it.

These three items add up to $5.15M. Without them, operating costs were $1.21M, up 11% from $1.09M. Within that, professional fees fell 24% to $0.76M. Staff costs rose to $0.31M from $0.08M, which the filing attributes to Acellent's staff and a management bonus. Board fees of $0.04M and listing fees of $0.09M were new.

What ADVB is now

Acellent develops "FinTruth", which the 10-K describes as software that checks AI-generated financial reports (credit analyses, research reports, financial statements) against their source documents. The filing calls it "the sole product offered to our customers." Acellent was a small company when it was bought: at acquisition its only asset was $12,891 in cash, and it had "no operations and no profit generation."

The first revenue doesn't come from software sales yet. The notes describe all $127,637 as an "agency fee", recognized at a single point in time, and say "the agency fee was one-off." From April to June 2026 Acellent itself lost $13,406. One fee of $0.13M against $1.21M of other operating costs doesn't yet show a business that can pay for itself. The 10-K gives no figures for customers, contracts or recurring revenue.

What the headline numbers hide

The gain is debt leaving the books, not cash arriving. At the time of sale, the three former subsidiaries together had liabilities exceeding their assets by $12.62M. Most of what they owed was owed to ADVB itself, as money lent between group companies ("intercompany" balances). While they were part of the group, those balances cancelled out in the combined accounts. Once the subsidiaries were sold, ADVB removed their $12.62M of net liabilities. It also released $0.88M of past currency-translation adjustments and added the $0.51M sale prices. Together those make the $14.02M gain. The cash flow statement points the other way: the Taiwan unit took $2.60M of cash with it when it was handed over, and its $490,000 price had not been paid by June 30. Disposing of the subsidiaries produced a net cash outflow of $2.58M.

The balance sheet is a bet on collecting from the companies it sold. "Prepaid expenses and other current assets" is $13.36M of ADVB's $13.75M of total assets. Inside it:

The receivable is carried at $12.96M. That is 94% of total assets and 106% of shareholders' equity ($12.28M), so without it equity would be negative. The debtors are businesses that, on the filing's own figures, owed more than they owned when they were sold for a combined $513,000. ADVB has marked down the receivable by about 14%. The filing itself calls the timing and amount of collections "significant to our liquidity", and management's view that it can fund the next twelve months "depends in part on expected collections."

Cash conversion: better than the loss, worse than the headline. Continuing operations used $0.96M of cash against a $6.26M reported loss. The gap is the $5.15M of non-cash charges above, plus a $0.58M inflow from lower prepaid balances, partly offset by $0.43M of lower payables. Across the whole group, including the biotech units before they left, operating cash outflow was $1.95M. Cash went from $2.90M (consolidated) to $0.39M.

Funding has been small, and mostly from insiders. The only equity raised for cash was $248,000, from a private placement in January 2026 at $1.24 a share. In the same year ADVB took in $1.08M of advances from related parties. These include the $600,000 loan from shareholder Jie Wang at 10% interest, which matures six months after its April 2026 disbursement and can be extended six months by mutual agreement. At June 30 ADVB owed related parties $1.08M in total, almost three times its cash.

One-offs in both years. Every big number this year is a one-off: the gain, the credit-loss provision, the CEO share award and the commitment fee. The prior year had none of comparable size. That makes the year-on-year comparison close to meaningless as a guide to the ongoing business.

Share count. Shares outstanding rose 53% in the year, from 1.08M to 1.65M (adjusted for the reverse split). The increase came from the private placement, the commitment-fee shares and the 270,000 shares issued for Acellent.

Controls. Management reports material weaknesses in internal control over financial reporting. A material weakness is a gap in the company's own checks that could let a significant error into the accounts. The weaknesses cited include too few trained finance and accounting staff. The auditor, WWC, P.C., gave a clean opinion with no going-concern paragraph. It was not engaged to audit internal controls.

Takeaway: ADVB's first "profitable" year is an accounting result of handing away its loss-making subsidiaries. The business that remains has $0.39M of cash and one $0.13M fee, and $12.96M of its $13.75M in assets is money owed by the companies it sold for $513,000. Whether that money is collected now matters more to the stock than anything the new AI business has shown.

Did last time's read hold up?

Our Q3 FY2026 report listed three things to watch in this 10-K:

• Whether the receivable from the former subsidiary would be written down: partly. ADVB recorded a $2.07M allowance against it. But the balance grew from $5.89M to a gross $15.03M, because selling the Taiwan unit turned another $8.60M of intercompany lending into a receivable from an outside owner. The question that report raised is now about a balance two and a half times larger.
• The going-concern opinion: resolved on paper. The Q3 filing said there was "substantial doubt" about ADVB's ability to keep operating. The 10-K drops that language, and management now says it has enough resources for twelve months, a view it says depends partly on collecting those receivables.
• The $600,000 loan due around October 2026: still open. It was outstanding at June 30 ($607,014 including interest), and the subsequent-events note mentions no repayment or extension.

Outlook

ADVB gives no revenue or earnings guidance. Its earlier forecast of "continuous loss for the next two to three years" related to the cancer-diagnostics business it has now exited. The next filing is the 10-Q for the quarter to September 30, 2026 (fiscal Q1 2027). Based on its 45-day filing pattern, it is due around mid-November 2026. Four things to watch:

1. Cash collected from former subsidiaries and the Taiwan buyer. This is the clearest test of whether the $12.96M asset is real. A further write-down would hit the same equity that the disposal gain created.
2. How the $600,000 loan was handled. It was due around mid-October against $0.39M of year-end cash, and the equity line that could have raised money was terminated in July.
3. Whether FinTruth produces recurring software revenue rather than one-off agency fees. Until it does, the continuing business runs about $1.2M a year of operating costs excluding the one-off charges against negligible income.
4. Further share issuance. With little cash and the equity line closed, more stock or related-party loans are the likely funding sources, so existing shareholders' stakes may shrink again.

Our view: this is now a very small AI start-up inside a listed shell. Its reported equity depends almost entirely on one receivable that is hard to collect. Until cash comes back from the former subsidiaries, or FinTruth shows repeat paying customers, the $5.33 of earnings per share says nothing about what the business can earn.